PDF(Pubmed)
Abstract：
With an estimated 1.88 million new cases and 0.92 million deaths in 2020, colorectal cancer accounts for nearly one-tenth of all new cancer and cancer-related deaths worldwide. Nearly half of the patients of colorectal cancer are diagnosed with metastatic or inoperable disease with a very dismal 5-year survival rate. Chemotherapy, targeted therapy, and immunotherapy have been used to treat metastatic disease, either alone or in combination. We present a case of recurrent metastatic colon carcinoma with KRAS exon 2 mutation and high microsatellite instability that was treated with a combination regimen of bevacizumab, capecitabine oral chemotherapy, and pembrolizumab immunotherapy. At nearly 5 years of treatment, the patient is alive with good performance status and improved quality of life owing to a favorable response to the molecular profiling-based treatment approach.
摘要：
2020年估计有188万新病例和92万人死亡，结直肠癌占全球所有新癌症和癌症相关死亡的近十分之一。将近一半的结直肠癌患者被诊断为转移性或无法手术的疾病，5年生存率非常低。化疗,靶向治疗,免疫疗法已被用于治疗转移性疾病，单独或组合。我们介绍了一例复发转移性结肠癌，具有KRAS外显子2突变和高度微卫星不稳定性，采用贝伐单抗联合治疗方案，卡培他滨口服化疗，和pembrolizumab免疫疗法。在近5年的治疗中，由于对基于分子谱分析的治疗方法的良好反应，患者还活着，表现良好，生活质量得到改善。
